PAR-24-133: Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to small businesses. Applications closed on November 17, 2025.
From the official notice on Grants.gov, last changed November 17, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR41 / R42
- Clinical trialsNot allowed
- Funded byNIAMS, NCATS, NHLBI
- Median yearly award$328,132
- Typical project length1 year
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under PAR-24-133 were run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 2 projects), National Center for Advancing Translational Sciences (NCATS, 1 project) and National Heart Lung and Blood Institute (NHLBI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-133 in the NIH Guide.
Key dates
| Posted | April 25, 2024 |
|---|---|
| Deadline | November 17, 2025 |
| Archived by Grants.gov | November 18, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 18 programs behind this notice (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Notice of Funding Opportunity (NOFO), the National Institutes of Health (NIH) aims to facilitate the career development and transition of investigators new to entrepreneurship with an interest in small business by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction. This NOFO supports small business concerns (SBCs) in employing and developing researchers as entrepreneurial Program Directors/Principal Investigators (PDs/PIs). In addition to augmenting scientific research staff and supporting research and development efforts at SBCs, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Optimal PDs/PIs for this award are scientists and professionals with strong research, technology development, and/or healthcare delivery skills and experience, but limited entrepreneurial and independent research project leadership experience. PDs/PIs are expected to grow their entrepreneurial skillset while working in a small business to develop promising technologies and products that align with NIH's mission to improve health and save lives.
Funded under PAR-24-133 so far
NIH funded 4 projects under PAR-24-133 in fiscal 2026, at 4 institutions. The median yearly award was $328,132.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Development of a modular customizable screening platform for chimeric antigenreceptor optimization | Sollus Therapeutics, Inc. | 2026 | $322,576 |
| Pre-Market Approval (PMA) Enabling Validation of a Diagnostic to Predict Immune Responses to AAV-based Therapies for GNE Myopathy and Broad Ranging Indications | Vecgen, Inc | 2026 | $333,689 |
| Diagnostic and Therapeutic Potential of LU-1001 for Coronary Microvascular Dysfunction | Lucier Pharmaceuticals Inc | 2026 | $606,311 |
| Identification of AAV capsids with superior skeletal muscle transduction capability using cross-species analysis model | Ventura Life Sciences, LLC | 2026 | $305,443 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Other programs behind this notice
- Drug Use and Addiction Research Programs
- Child Health and Human Development Extramural Research
- Vision Research
- National Center for Advancing Translational Sciences
- Arthritis, Musculoskeletal and Skin Diseases Research
- Alcohol Research Programs
- Human Genome Research
- Environmental Health
- Research Related to Deafness and Communication Disorders
- Oral Diseases and Disorders Research
- Nursing Research
- Research and Training in Complementary and Integrative Health
- Medical Library Assistance
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-133 still open?
No. It closed on November 17, 2025.
Who can apply for Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)?
Closed November 17, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-24-133?
NIH RePORTER lists 4 projects funded under PAR-24-133 in fiscal 2026, at 4 institutions. The most were at Sollus Therapeutics, Inc., Vecgen, Inc, Lucier Pharmaceuticals Inc.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)